Testing a new drug for liver cancer after prior treatment
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called BB102 for people with liver cancer (HCC) that has grown after at least one previous treatment. The drug targets a specific protein (FGF19) that may be fueling the cancer, and doctors want to see if it can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your liver cancer must have progressed after at least one prior treatment that included drugs like sorafenib, lenvatinib, or immunotherapy (e.g., PD-1/PD-L1 inhibitors), or you could not tolerate that treatment.
- Your tumor must show high levels of a protein called FGF19 (a lab test is needed).
- Your cancer must be at a stage where it can be treated with systemic (whole-body) therapy, not just local treatment.
- You need to have at least one tumor that can be measured on a scan.
- You must be in reasonably good health — able to care for yourself and out of bed at least half the time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ACE723, which is designed to specifically attack liver cancer cells while sparing healthy cells. It is for people with advanced liver cancer that has not responded to or has worsened after standard treatments that included immunotherapy.
This trial tests a new drug, ABSK-011, combined with standard care, against a placebo with standard care for people with advanced liver cancer that has a specific marker called FGF19 overexpression. The goal is to see if ABSK-011 can help slow the disease.
This trial tests a new drug called SH006 combined with another treatment against a standard drug (regorafenib) for advanced liver cancer. It is for people whose cancer has stopped responding to immunotherapy, and the goal is to see if it helps them live longer or shrinks the tumor.
This trial tests a new drug that combines two immune system boosters to shrink liver cancer that has come back after surgery. The goal is to make a second surgery more effective.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a new drug called HH-009 for advanced or inoperable liver cancer (hepatocellular carcinoma, or HCC) that has a specific genetic marker called FGF19. The drug is designed to target this marker and may help slow or shrink the cancer in people whose disease has gotten worse despite previous treatment.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.